Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre
Registry Page 1 Clinical and Experimental Rheumatology 2015; 33: 449-456. Efficacy and …

Objective A number of open‐label studies have suggested the potential benefit of rituximab
(RTX) in systemic lupus erythematosus (SLE). However, in 2 recent randomized controlled …

The wide spectrum of clinical manifestations and high relapse rate represent a therapeutic
challenge in systemic lupus erythematosus (SLE). Observational studies suggested efficacy …

Objective Conventional treatment of systemic lupus erythematosus (SLE) and lupus
nephritis (LN) is associated with damage accrual, hence increased morbidity rate. Off-label …

Objectives Rituximab (RTX) is a biological treatment used off-label in patients with systemic
lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in …

The complexity of the therapeutic approach in systemic lupus erythematosus (SLE) is
increased by the large number of patients who do not respond to the first-line therapies and …

Objective The objective of this article is to evaluate the safety and clinical outcome of
rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of …

Objective B cells are likely to contribute to the pathogenesis of systemic lupus
erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III …

Background The clinical outcomes following rituximab (RTX) treatment in patients with
systemic lupus erythematosus (SLE) is highly variable. We aimed to identify predictive and …

Objectives To describe the baseline characteristics of SLE patients requiring biologic
therapy in the UK and to explore short term efficacy and infection rates associated with …